F028 Respect the Dormant Beast: Optimize Your Management of High-risk Cutaneous SCCs
DESCRIPTION
Approximately 5% of cutaneous SCCs (cSCCs) harbor high-risk features. The rate of nodal metastasis and disease-specific death for cSCCs are 4% and 1.5%, respectively. This session, designed for general dermatologists and dermatologic surgeons, will discuss clinical, histological and molecular features of high-risk cSCCs by reviewing outcomes and limitations of current staging systems and gene expression profiling. Participants will learn how to improve management of cSCCs based on tumor risk stratifications and host factors, and update their knowledge on topics of field cancerization, nodal staging, radiologic imaging, post-operative adjuvant therapy and immune checkpoint inhibitors for high risk and advanced cSCCs.
LEARNING OBJECTIVES
Recognize clinical, histological and molecular features of high-risk cSCCs, and review outcomes and limitations of current staging systems and gene expression profiling.
Outline opportunities to improve management of cSCCs based on tumor risk stratifications and host factors, using field therapy, radiologic and nodal staging, and post-operative adjuvant therapy.
Discuss advances in the management of unresectable and metastatic cSCCs.
SCHEDULE
3:30 PM
Prevention
Anokhi Jambusaria-Pahlajani, MD, MS, FAAD
4:00 PM
Workup, Staging, and Prognostics
Vishal Patel, MD
4:30 PM
Surgical Management
Addison Michael Demer, MD, FAAD
5:00 PM
Non Surgical Management
Emily S Ruiz, MD, FAAD
DIRECTOR
Emily S Ruiz, MD, FAAD
SPEAKERS
Addison Michael Demer, MD, FAAD
Anokhi Jambusaria-Pahlajani, MD, MS, FAAD
Vishal Patel, MD
DISCLOSURES
Addison Michael Demer, MD, FAAD
Dermavision Solutions – Investigator(Patent royalties or other compensation for Intellectual Property Rights); SkinVision – Investigator(Patent royalties or other compensation for Intellectual Property Rights); Triangulate Labs – Investigator(Patent royalties or other compensation for Intellectual Property Rights);
Anokhi Jambusaria-Pahlajani, MD, MS, FAAD
Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria);
Vishal Patel, MD
Almirall – Speaker(Honoraria); Gerson Lehrman Group – Consultant(Fees); Regeneron – Speaker(Honoraria); Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria), Speaker(Honoraria);
Emily S Ruiz, MD, FAAD
Almirall – Consultant (1099 relationship)(Fees); Castle Biosciences, Inc – Investigator(Grants/Research Funding); Checkpoint Therapeutics – Consultant (1099 relationship)(Fees); Feldan Therapeutics – Consultant (1099 relationship)(Fees); Merck – Investigator(Grants/Research Funding); Regeneron – Advisory Board(Fees), Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Fees), Consultant (1099 relationship)(Fees);